New diagnostics spin-out Spectromics Limited formed from UPF PoP project

1 May 2014

University of Manchester spin-out, Spectromics Limited, set to develop novel technology for effective use of antibiotics and other antimicrobial therapeutics.

The formation of Spectromics is the result of three years of research by Professor Roy Goodacre of the Institute of Biotechnology and School of Chemistry at The University of Manchester, and Dr Mathew Upton, School of Biomedical and Healthcare Sciences, Plymouth University Peninsula Schools of Medicine and Dentistry, formerly at the School of Inflammation and Repair at The University of Manchester. Both are Directors of the company.

The technology, relating to rapid diagnostics for antimicrobial susceptibility testing, will allow doctors to determine the most effective drug to be prescribed for each patient, bringing a personalised medicine approach to the widespread use of antibiotics.

Read full article